We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Restricted dose and duration of use.
Increased risk of stroke in older women should be taken into account in prescribing decisions.
We're looking for your views on how medical devices will be regulated across the United Kingdom (UK) in the future.
First published during the 2019 to 2022 Johnson Conservative government
The main decision-making, executive and managerial bodies at the Medicines and Healthcare products Regulatory Agency (MHRA).
Guidance to help applicants and licence holders get and maintain a manufacturer licence - MHRA guidance note 5.
Latest news and press releases, information on meetings and events, public consultations and related patient safety information.
Information for clinicians and patients.
Following a review of the risks associated with use of opioid medicines for non-cancer pain, the Commission on Human Medicines (CHM) has recommended that fentanyl transdermal patches are contraindicated in opioid-naive patie…
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
UK approved bodies listed under Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002).
Risk of venous thromboembolism (VTE) for drospirenone-containing combined oral contraceptives (COCs), including Yasmin, is higher than for levonorgestrel-containing COCs.
Relevant safety information for users of magnetic resonance imaging (MRI) equipment in clinical use.
Do not stop your hypertriglyceridemia treatment without a discussion with your doctor
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
MHRA sets out new plans to protect patient safety and enable access without delay for UK patients to innovative medical technologies
Guidance on the decentralised and mutual recognition reliance procedure (MRDCRP) for marketing authorisation applications including information on how to apply.
The MHRA was alerted by Beyond Compliance and the UK National Joint Registry (NJR) to a significantly higher revision rate observed with the ORIGIN PS patient-matched total knee replacement.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).